A study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day ...

Mission Therapeutics is down to its clinical assets MTX652 and MTX325, which work by disabling a key enzyme that interferes ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

Transplanting insulin-producing cells along with engineered blood-vessel-forming cells has successfully reversed type 1 ...

Inventiva (IVA) announced the publication in Biomedicine & Pharmacotherapy, a peer-reviewed, scientific journal, of the results from a ...